Merck ayudará a Johnson & Johnson is a producer of more vacant contrast with COVID-19

Washington. The Merck & Co. pharmaceutical company helped its rival Johnson & Johnson produce its proven vaccine against the coronavirus, in order to be able to sum up more quickly, confirmed on March a staff member of the governing state.

The announcement surges while United States steps in to boost Johnson & Johnson’s vaccine production, which requires a single injection. Officials say J&J has two problems and only produced 3.9 million doses before receiving the Saturday emergency authorization. The company claims that it is planning to produce 100 million doses for the end of June.

Last week, an interpellation in Congress, J & J’s Vice President Richard Nettles declared that the company had suffered “significant challenges” in its production due to its “extremely complicated” manufacturing process.

Merck’s offer will probably help J&J to supplement its production methods and increase its sum, but now the governor has not given details.

Check out the chairman of Joe Biden discussing the theme and a discourse la tarde del martes. The governing body calculates that there will be sufficient doses of the three vacancies approved for inoculation to all eligible citizens for the June journals, even if the vacancies to the medical centers could be delayed a little longer.

No clear explanation will be given as to the effect of Merck’s aid to the summit of the injectors. Previously, federal officials announced that they would be able to install the complicated production lines.

A second official source indicates that Merck will dedicate plants to the production process: one to equip the vacancy and the other to collocate the situation in terms and apply quality checks.

The official sources that disclose Merck’s intentions are conditional on anonymity. The Washington Post was the first to announce.

Merck has been suspended since Merck’s plans to roll out a vacancy, despite the results of its trials being compared to those of other companies. Announcement in these cases that it is focusing on treatment against COVID-19.

Compared to the Moderna and Pfizer vacancies, the J&J requires a sole injection and is less complicated to administer, converts in key clause of the state plan to export the remedy to the rest of the world, even if only one state is in the state . The J&J vaccine is required to be released at freezing temperatures, and does not require the patient to regenerate any incontinence during a second injection.